Stocks · News reference
Crude Oil Down 3%; XPeng Shares Fall After Q2 Results
US stocks traded mixed with the Dow Jones index gaining over 150 points. Consumer staples shares jumped while information technology stocks fell. XPeng Inc shares fell 7% due to wider than expected loss and lower revenue outlook.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Shares of fiber-optic connectivity companies are trading lower as elevated Treasury yields and increased Fed rate-hike expectations following this week's latest inflation data weigh on technology stocks. Elevated borrowing costs could pressure AI infrastructure spending plans, raising concerns about future demand for fiber-optic equipment and connectivity solutions.
Why Applied Optoelectronics Stock Plummeted This Week
Applied Optoelectronics stock fell 23.6% this week after Broadcom CEO warned of capital constraints that could slow AI infrastructure spending. The optical component maker, which relies heavily on data center customers for 800G transceivers, faces headwinds from funding concerns among major cloud providers. The stock has declined 64.2% from its 52-week high, compounded by recent shareholder dilution from a $600 million equity offering.
Applied Optoelectronics shares are trading lower after B. Riley Securities lowered its price target on the stock from $109 to $92.
Alvotech to Report Financial Results for the Nine-Month Period to September 30, 2026
Alvotech announced it will release its financial results for the nine months and third quarter ended September 30, 2026, on November 11, 2026.
Alvotech birtir uppgjör fyrstu níu mánaða ársins 2026 þann 11. nóvember nk.
Alvotech announced it will release its nine-month financial results for 2026 on November 11, with a live webcast presentation scheduled for November 12. The company also received FDA approval for an enhanced SIMLANDI® manufacturing process that more than doubles output per batch, increasing manufacturing productivity and freeing capacity to support growing demand across its biosimilars portfolio.